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1. Introduction 
Neuroendocrine Tumors (NETs) constitute a heterogeneous group of neoplasms which 
originate from neuroendocrine cells of diffuse endocrine system. They may synthesize, 
store, and secrete peptides and neuroamines that can cause distinct clinical syndromes. On 
the other hand, many are clinically silent until late presentation with mass effects (1).  
Gastro-Entero-Pancreatic (GEP) NETs originate from both pancreatic islet cells or 
gastroenteric tissue (from diffuse neuroendocrine cells distributed throughout the gut) and 
are rare neoplasms, representing about 2% of all the gastrointestinal tumors. Due to their 
rarity, they are difficult to diagnose and the begnning of the diagnostic process is often 
based on the measurement of circulating markers, before planning expensive and invasive 
diagnostic tests (2, 3). A critical point is that the frequent late diagnosis of NETs is due to 
failure to identify symptoms or to establish the biochemical diagnosis; in fact 60-80% of 
NETs are metastatic at diagnosis. A prompt identification by the use of specific biomarkers 
is therefore useful to recognize these tumors (1).  
Circulating tumor biomarkers can be divided into general and specific biomarkers. The 
neuroendocrine cells that give rise to NETs have many common features, including the 
synthesis of peptides, biologically inactive, that act as general markers, but have also the 
capacity to secrete a variety of specific biomarkers that characterize a precise biochemical 
function (4). Individual amines and peptide hormones are indeed specific to certain types of 
NETs (Table 1). 
2. General biomarkers 
There are several families of secretory proteins found in high concentrations  
in neuroendocrine cells and, in particular, neuroendocrine tumor cells. 
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They include the granins, neuron specific enolase (NSE), and pancreatic polypeptide (PP). 
Both chromogranin A (CgA) and NSE show increased concentration levels in many patients 
with NETs, but CgA is recognized as the most effective and the only general biomarker that 
has been extensively investigated (1-5). 
 
Tumor Site Syndrome Symptoms Biomarkers 
Gastric (type 1 and 2) None Upper GI CgA, gastrin 
Gastric (type 3) None Upper GI CgA 
Duodenal Zollinger-
Ellison  
Epigastric pain, peptic ulcer, 
diarrhea, GERD  
CgA, gastrin (>50%), PP 
(35%),  
Somatostatin (<10%) 
Ileal Carcinoid Diarrhea, flushing, sweating CgA, serotonin, NKA 
and SP, 5HIAA 
Appendix Carcinoid  Diarrhea, flushing, sweating CgA, serotonin, HIAA, 
NKA 
Rectal None None CgA, PYY(10%) 
Meckel diverticulum Zollinger-
Ellison  
Epigastric pain, peptic ulcer, 
diarrhea  
CgA, gastrin (>50%) 
Pancreas    
   Insulinoma Whipple’s 
triad 
Hypoglycemia, dizziness, 
sweating 
CgA, insulin, pro-
insulin, C-peptide 
   Gastrinoma  Zollinger-
Ellison 
Epigastric pain, peptic ulcer, 
diarrhea 
CgA, gastrin, PP (35%) 
   VIP-oma WDHA Watery diarrhea CgA, VIP 
   Glucagonoma None Necrolytic migratory 
erythema 
CgA, glucagon, 
glycentin 
   Somatostatinoma None Mild diabetes, gallstones CgA, somatostatin 
   PP-oma None None CgA, PP 
Non functioning None None CgA, PP 
CgA=Chromogranin A; 5-HIAA= 5-hydroxyindoleacetic acid; PP= Pancreatic polypeptide; VIP= 
vasointestinal peptide; NKA= neurokinin A; PYY= peptide YY 
Table 1. Syndromes, symptoms and secretory products from GEP NETs 
2.1 Granins 
The chromogranin family consists of at least three different water soluble acidic 
glycoproteins (CgA, CgB, and secretogranin II, sometimes called chromogranin C). These 
proteins are 27 to 100 kDa in size and contain 10% acidic (glutamic or aspartic acid) 
residues, as well as multiple single  and dibasic amino acid residues. All of the granins are 
found as major components of the soluble core of dense-core secretory granules in NE cells 
and are secreted from these cells in a physiologically regulated manner.  Granins are major 
constituents of large dense-core secretory vesicles and are co-secreted with peptide 
hormones and amines. Electron dense or translucent secretory granules are in fact 
prototypical features of the neuroendocrine cells (1-6). 
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2.1.1 Chromogranin A (CgA) 
Chromogranin A (CgA) has been claimed to be the best general neuroendocrine marker so 
far available. CgA is a 49 kDa monomeric, hydrophilic, acidic glycoprotein of 460 amino 
acid and is widely expressed in neuroendocrine cells, where it constitutes one of the most 
abundant components of secretory granules, and it is secreted from neuroendocrine-
derived tumors including functioning and non-functioning GEP NETs, 
pheochromocytomas, neuroblastomas, medullary thyroid carcinomas and some pituitary 
tumors. CgA is secreted to the extracellular space, so it's easily detectable in the blood. 
CgA is co-secreted with the amines and peptides that are present in the neurosecretory 
granules even if it can be elevated in both functionally active and non-functional NETs. 
CgA seems to be a “common denominator” peptide in all the components of the diffuse 
neuroendocrine system (7).  
The precise function of CgA remains unknown, but it is thought to be involved in the 
packaging and processing of neuropeptide precursor and peptide hormones. It may also 
play a role in the organization of the secretory granule matrix. Moreover CgA has diverse 
physiological interactions: CgA (or its derivatives) is an inhibitor of catecholamine, insulin, 
and leptin, having a role in carbohydrate and lipid metabolism; moreover it inhibits 
parathormone secretion; on the other hand, CgA increases glucagon and amylase release. In 
addition to its effects on endocrine organs, CgA also regulates reproductive functions and 
has a role also in the regulation of cardiovascular function: CgA elevations have been 
reported in essential hypertension (CgA levels correlates with the severity of hypertension) 
and in chronic heart failure correlating with grade of cardiac dysfunction and mortality. A 
role of CgA in the regulation of inflammatory response has also been described. In fact 
increased CgA levels correlate with serum TNF-ǂ receptor levels in a number of 
inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, 
systemic lupus erythematosus, chronic obstructive pulmonary disease and chronic heart 
failure. Patients with sepsis show the highest increase of CgA; CgA positively correlates 
with inflammatory markers as C-reactive protein and procalcitonin. It remains to be 
elucidated the pathophysiological relevance of these correlations. Some authors suggest that 
CgA participates in a negative feedback that limits the activation of endothelial cells (1). 
Circulating CgA concentrations are sensitive even if non specific markers of NETs. CgA has 
been reported to be more sensitive than urinary 5-hydroxyindoleacetic acid (5-HIAA) as 
well as than pancreatic polypeptide concentrations. The highest values were noted in ileal 
NETs (200 times the upper normal limit) and IN GEP-NETs associated with MEN1 (150 
times the upper normal limit) while gastric type I, pituitary, and parathyroid tumors had 
lower values (ranging from 2 to 4 times normal). Both functioning and nonfunctioning 
pancreatic NETs had intermediate values (60–80 times the upper limit of normal) as did 
Zollinger- Ellison Syndrome (ZES), multiple endocrine neoplasia (MEN)-1, type II and III 
gastric entero-chromaffin-like (ECL)omas (80–100 times normal). It has also been proposed 
that CgA is more frequently elevated in well-differentiated tumors compared to poorly 
differentiated tumors of the midgut, suggesting that the loss of CgA expression in poorly 
differentiated neuroendocrine carcinomas indicates their incomplete or partial endocrine 
differentiation. In fact, poorly differentiated NE carcinomas rarely express CgA because of 
the rarity of large, dense-core granules. The presence of high plasma levels of CgA at  
diagnosis is an independent prognostic factor that indicates a reduced overall survival. 
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Effective treatment is often associated with decrease in CgA values. CgA correlates with 
tumor burden and recurrence. Measurement of CgA may help in the effective diagnosis of 
NET and has a major utility in predicting disease recurrence, outcome, and efficacy of 
therapy, so delineating the prognosis (5). 
Elevated CgA can occur in normal individuals and in patients with non-NET tumors, 
although the levels are usually lower than in patients with NET. Less than 1% of CgA tests 
that are more than 20 times greater than the reference range are false positive. Levels of CgA 
secretion vary on a day-to-day basis in healthy subjects as well as in individuals with NETs. 
The mean day-to-day variation of CgA is approximately 25%. Food intake may increase 
CgA levels, therefore, CgA should be measured in fasting patients to ensure standardization 
of the results. There are conflicting results on the impact of exercise on CgA. Significant 
increases in CgA concentration have been reported in healthy subjects, but in patients with 
heart disease, long-term exercise had no impact on CgA. Finally extreme physical stress also 
causes CgA elevations. High-serum levels of CgA have also been demonstrated in patients 
with other malignancies including colon, lung, breast, liver and prostate cancer. Overall 
CgA has been found to be clinically informative and moderately sensitive in the majority of 
the studies, and more sensitive than NSE. In prostate cancer elevated CgA seems to indicate 
a poor prognosis; in small-cell lung carcinoma CgA levels were more frequently elevated 
and were also higher in cases of more extensive disease; NE differentiation occurs in 34% of 
primary colorectal cancer (1). 
False-positive elevation of CgA may also occur in the following non-neoplastic 
circumstances: impaired renal function, Parkinson disease, untreated hypertension and 
pregnancy, steroid treatment or glucocorticoid excess, chronic atrophic gastritis (type A), 
treatment with proton pump inhibitors (PPI), inflammatory bowel disease, liver disease, 
hyperthyroidism. In renal failure CgA increases due to a decreased plasma clearance, 
reaching levels found in neuroendocrine neoplasia. In autoimmune chronic atrophic 
gastritis, elevated circulating CgA levels are caused by chronic hypergastrinemia and 
stimulation of ECL cell proliferation. Raised circulating CgA levels in addition to raised 
gastrin in atrophic gastritis, confounds the diagnosis of gastrinoma in many patients who 
present with dyspeptic symptoms. But the major cause of elevated CgA levels is the 
widespread use of PPIs and other acid suppressive medications. All PPI users, even with 
low dosage (10 mg/d) have elevated fasting CgA levels. The normalization of CgA levels 
occurs by withdrawal of PPI in 1-2 weeks (1, 10). 
There is no universal standard calibration for serum or plasma chromogranin A assays. In 
addition, different chromogranin A assays, which use different antibodies or antibody 
combinations, will display different cross-reactivity with the various chromogranin A 
fragments. Therefore, reference intervals and individual patient results differ significantly 
between different chromogranin A assays and cannot be directly compared. Several 
commercially available radioimmunoassays (RIAs) and enzyme-linked immunosorbent 
assays (ELISAs) have been developed for the measurement of circulating  
CgA concentrations. Moreover many diagnostic laboratories use in-house assays. The three 
main different commercial kits are CgA-RIA CT (CIS Bio International, Gif-sur-Yvette 
Cedex, France), Dako CgA ELISA kit (Dako A/S, Glostrup, Denmark), and CgA 
EuroDiagnostica (ED) (Malmo¨, Sweden). All three assays use different standards. In the CIS 
kit, CgA concentration is expressed in ng/ml and normal range is < 99g/l, while with the 
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Dako assay results are expressed in U/l, and normal range is within 19 U/l; with the ED kit 
CgA levels are expressed in nmol/l and normal range is < 41 nmol/l. Concerning plasma 
and serum measurement, a strong positive linear relationship has been reported between 
plasma and serum CgA values, indicating that CgA measurement can be undertaken in both 
sample types. In conclusion, because CgA concentrations are of considerable clinical 
relevance, substantial characterization and standardization to ensure uniform reporting are 
needed (1, 7, 8). 
2.1.2 Other granin family peptides 
The granin family comprises eight members including CgA and its derivated peptides, CgB, 
CgC (secretogranin II [SgII]), SgIII, SgIV, SgV, SgVI and VGF, but their value as circulating 
markers for endocrine tumors has not been investigated extensively extensively (1).  
Several other CgA-derived peptides, resulting by posttranslational processing have been 
isolated from extracts of human endocrine tumors. These molecules results in a series of 
smaller biologically active peptides, such as pancreastatin (corresponding to CgA residues 
250–301), catestatin (corresponding to CgA residues 352–372), and vasostatin I and II 
(corresponding to CgA residues 1–76 and 1–113, respectively). These CgA derived peptides 
affect secretion of other hormones, play a role in vasoconstriction, and regulate metabolism. 
Among them, the most clinically interesting is pancreastatin. An endoprotease, the 
prohormone convertase-1 (PC-1), is involved in the processing of the precursor protein 
chromogranin A (CGA) to a smaller peptide called pancreastatin (PST), a 49-aminoacid 
peptide that inhibits insulin secretion, somatostatin release, exocrine pancreatic secretion 
and gastric acid secretion. PST is found in human stomach- and colon extracts and in a liver 
metastasis of gastrinoma. Pancreastatin was used before the complete sequence of CgA had 
been elucidated and before there were any reliable assays that could measure the whole 
molecule of CgA, as an epitope for antibody production. Pancreastatin antisera were used in 
immunohistochemistry and RIA to assess the presence of CgA in cells and the concentration 
of CgA in the circulation. But pancreastatin levels do not equale to CgA concentrations in 
the circulation. The molecule was found to be significantly increased in patients with NETs 
metastasized to the liver and concentrations are proportional to the number of hepatic 
metastases. Monitoring of liver metastases may remain the main advantage of pancreastatin 
assay (2). It is interesting that pancreastatin is not increased in patients with gastric 
achlorhydria or hypochlorhydria. Thus, false-positives are less problematic with the 
pancreastatin assay. It may be a very early biomarker for liver tumor activity, even when 
CgA is normal (5).   
CgB is the second most abundant member of the chromogranin family. Like CgA, it is a 
strongly acid protein containing approximately 25% acidic amino acid residues. It has 14 
dibasic cleavage points  but has been less well studied than CgA. Unlike CgA, CgB does 
not seem to have increased concentrations in patients with renal failure, in patients with 
atrophic gastritis, or those receiving acid-suppressing therapy. The interest to measure 
CgB in addition to CgA in patients with GEP NETs is therefore increased. Moreover, in 
tumors where CgA is not found, CgB may be increased. Such patients include those with 
MEN 1 and those with tumors in the duodenum or rectum. In addition, CgB is a major 
granin of the human adrenal medulla and may be a more sensitive marker of 
pheochromocytomas (2, 5).  
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Fig. 1. The granin family and fragments of CgA. The 8 granin proteins include 
chromogranin A, CgB, CgC (SgII), SgIII, SgIV, 7B2 (SgV), neuroendocrine secretory protein 
55 (NESP55 or SgVI), and VGF nerve growth factor–inducible (VGF).  
2.2 Pancreatic polypeptide (PP) 
Circulating PP is a single chain, 36-aminoacid peptide arising from the PP cells of the 
pancreas and is expressed in neuroendocrine cells of the gut and the pancreas. The function 
of PP is to self regulate pancreatic secretion activities (endocrine and exocrine), it also has 
effects on hepatic glycogen levels and gastrointestinal secretions. 
Elevated PP concentration are found in patients with NETs, both pancreatic (20-50%) and 
gastrointestinal carcinoids (30-50%). Before methods for the measurements of CgA were 
available, PP was used as a general marker for endocrine tumors, although it is poorly 
specific. PP is now useful in the diagnosis and monitoring of NETs where no other general 
marker is raised and in PP-omas. High levels of circulating PP can also be found in diabetes, 
renal impairment, chronic inflammation, alcoholism and in elder patients. Its secretion is 
increased after a protein meal, fasting, exercise, and acute hypoglycemia and is decreased by 
somatostatin and intravenous glucose (2, 11). 
2.3 Neuron Specific Enolase (NSE) 
NSE is the neuron-specific isomer of the glycolytic enzyme 2-phospho-D-glycerate 
hydroxylase or enolase. This isomer is present in neurons and neuroendocrine cells and can 
be used as a biomarker for tumors derived from these cells. As well as CgA, NSE is a marker 
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useful for the diagnosis and the monitoring of patients with neuroendocrine tumors 
(especially neuroblastoma, small cell lung cancer, less important for GEP NETs); it has other 
several applications, including the assessment of neuronal damage during stroke. Elevated 
NSE levels are indicative of poorly differentiated tumors. NSE levels seems not to be related 
to any secretory activity of the tumor (11, 12).  
3. Specific biomarkers 
In addition to general markers, there are biomarkers specific for particular GEP-NET 
associated syndromes. The most typical is carcinoid syndrome and the specific marker is 5-
Hydroxyindole Acetic Acid. Other specific markers including insulin, gastrin, vasoactive 
intestinal peptide, glucagon, bradykinin, substance P, neurotensin, human chorionic 
gonadotropin, neuropeptide K, and neuropeptide L are each of some value in precisely 
defining the functionality of individual NETs (see above Table 1). 
3.1 5-Hydroxyindole acetic acid (5-HIAA) 
5-HIAA is the urinary breakdown of serotonin, which is synthesized and stored in 
enterochromaffin cells of the gastrointestinal tract (80% of total body serotonin content), in 
dense granules of platelets and in the serotoninergic neurons of the central nervous system. 
Serotonin is a ubiquitous tryptophan-derived biogenic amine, involved in homeostasis, 
vasoconstriction and neurotransmission (7).  
Carcinoid syndrome is the typical clinical picture of metastatic ileal carcinoid, occurring in 
about 18% of patients and is characterized by flushing, diarrhea, abdominal pain; less 
frequent events are lacrymation, profuse sweating, telangiectasias, cardiac fibrosis, and 
cutaneous manifestations pellagra-like due to lack of niacin. This syndrome is caused by the 
massive release of serotonin, which is no longer metabolized in the liver, and other 
substances, such as tachykinins, prostaglandins, and bradykinins (3) (Table 2). 
 
Clinical features (%) Characteristics Mediators 
Flushing 90 Foregut tumors: 
prolonged fit, red-purple, 
localized to face and trunk. 
Midgut tumors:  
quick fit, pink-red. 
Serotonin, histamine,  
P substance, 
prostaglandins  
Diarrhea 70 Secretory Serotonin, histamine, VIP, 
prostaglandins, gastrin 
Abdominal pain 40 Long lasting Obstruction, 
hepatomegaly, intestinal 
ischemia, fibrosis 
Profuse sweating 15  Serotonin, histamine 
Telangiectasias 25 Face Unknown cause 
Heart disease 30 (right) 
 
10 (left) 
Valvulopathies (tricuspid 
valve, pulmonary valve). 
Right heart failure. Dyspnea
P substance, serotonin 
Pellagra 5 Dermatitis deficit of niacin 
Table 2. Characteristics of carcinoid syndrome 
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This syndrome is typical of metastatic well-differentiated midgut NETs, even if other clinical 
conditions may mimic symptoms and signs (Table 3).  
Clinical Condition Tests 
Carcinoid CgA, Serotonin, 5-HIAA, PP, VIP 
VIP-oma CgA, PP, VIP 
Medullary carcinoma of the thyroid CgA, CEA, Calcitonin, Ca++ infusion, RET 
proto-oncogene 
Pheocromocytoma CgA, Plasma free metanephrines, urine 
metanephrines, VMA, Epi, Norepi, glucagon 
stimulation, MIBG 
Diabetic autonomic neuropathy HRV, 2hs PP glucose 
Menopause FSH 
Epilepsy EEG 
Panic attack Pentagastrin, ACTH 
Mastocytosis Plasma histamine, urine tryptase 
Mitral valve prolapse Cardiac echo 
CgA=Chromogranin A; 5-HIAA= 5-hydroxyindoleacetic acid; PP= Pancreatic polypeptide; VIP= 
vasointestinal peptide; CEA= carcino-embryonic antigen;  VMA= vanillylmandelic acid; Epi= 
epinephrine; Norepi= norepinephrine; MIBG= metaiodobenzylguanidine; HRV= heart rate variability; 
2hs PP= 2-hour postprandial blood sugar; FSH= follicle-stimulating hormone; EEG= 
electroencephalography; ACTH= adrenocorticotropic hormone. 
Table 3. Differential diagnosis of flushing and diagnostic tests 
The 24-h measurement of 5-HIAA is a useful specific marker for serotonin-producing NETs. 
The overall sensitivity and specificity of urinary 5-HIAA in the presence of the carcinoid 
syndrome is 70 and 90%, respectively. Therefore this marker is the most frequently 
performed assay in the clinical setting of the carcinoid syndrome. Midgut carcinoids are 
most liable to produce the carcinoid syndrome with 5-HIAA elevation, thus attesting to a 
high specificity in this setting (approximately 75% of midgut NETs are associated with a 
positive urinary 5-HIAA test). Functional symptoms in NETs originating from the midgut  
are in fact mostly due to the secretion of  5-hydroxytryptophan (5-HTP) or serotonin. The 
sensitivity is lower in patients with midgut carcinoid tumors without the carcinoid 
syndrome and in patients with fore- and hindgut NETs due to less serotonin production 
from these tumors than midgut ones. Elevated 5-HIAA levels in the urine are highly 
suggestive of an ileal NET, although some NETs found in the lung and pancreas also secrete 
serotonin (7, 11).  
High-performance-liquid-chromatography (HPLC) with electrochemical detection is 
currently recommended to measure 5-HIAA. In some laboratory automated assays or those 
using mass spectrometry are available.  
There are false positive 5-HIAA urinary levels as well as false negative ones. Some foods 
contain high levels of serotonin which may increase the levels of urinary 5-HIAA and their 
consumption should be avoided 3 days prior to urine collection (i.e. plums, pineapples, 
bananas, eggplants, tomatoes, avocados, and walnuts). For this reason patients need to be 
on a diet free of tryptophan/serotonin-rich foods to avoid false elevations in urinary 5-
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HIAA. Untreated patients with malabsorption (celiac disease, tropical sprue, Whipple 
disease, intestinal stasis and cystic fibrosis), may have increased tryptophan metabolites. 
Also certain medications may interfere with the assay: paracetamol, fluorouracil, 
methysergide, naproxen and caffeine may cause false positive results. On the contrary 
levodopa, aspirin, adrenocorticotrophic hormone (ACTH), methyldopa, and phenothiazines 
may give a false negative results (13).  Somatostatin analogs are known to decrease levels of 
5-HIAA. Moreover, patients with renal impairment  and those with hemodyalisis may have 
falsely low 5-HIAA levels. 
5-HIAA does not seem to be a useful prognostic factor in patients with carcinoid syndrome, 
because of the fluctuating release of serotonin in NETs of the midgut. On the other hand, 
several studies found high 5-HIAA levels to be an independent survival factor. Overall, in 
these studies, higher concentrations of urinary 5-HIAA are associated with a worse 
prognosis, and persistently low 5-HIAA excretion predicts more favorable survival in 
patients with disseminated disease. The intra-individual variation of 5-HIAA may be high. 
When the collection is required for the diagnosis it is useful to have two consecutive 24-
hours collections and to take the mean value (7).  
Serotonin plays a key role in development of peritoneal and cardiac fibrosis via activation of 
the 5HT2B receptor and a cascade of connective tissue growth factors. Reductions in plasma 
serotonin levels correlate with a decreased incidence of carcinoid heart disease (CHD). 
Moreover, urinary 5-HIAA excretion also correlates with the severity of CHD and prognosis 
in patients with carcinoid syndrome.  
3.2 Insulin 
Insulin is a peptide hormone composed of 51 amino acids and has a molecular weight of 
5808 Da. It is produced in the islets of Langerhans in the pancreas, within the ǃ-cells. In ǃ-
cells, insulin is synthesized from the proinsulin precursor molecule. Insulin is a hormone 
central in the regulation of carbohydrate and fat metabolism in the body. Since the main 
action of insulin is reducing blood glucose levels, by increasing glycogen synthesis and 
promoting storage of glucose in liver (and muscle) cells, insulin excess (such as an 
insulinoma) induces hypoglycemia. In patients with suspected insulinoma, the insulin and 
its precursors or breakdown products should be tested, even if  further biochemical tests 
include the 72-hour fast, which is the gold standard for establishing the diagnosis of 
insulinoma. Insulinomas secrete proinsulin, insulin and C-peptide intermittently, and, 
although insulin concentrations in the circulation may often be within reference range, 
insulin is at most times inappropriately high for the blood glucose concentration (14). 
Insulinoma is the most common secretory NET of the pancreas that produces a symptomatic 
clinical syndrome. More than 80% of insulinomas are benign. Insulinoma is uncommon, 
although it is the second most common pancreatic NET to occur in patients with MEN1 (5).  
3.3 Gastrin 
Gastrin is a hormone that stimulates secretion of gastric acid (HCl) by the parietal cells of 
the stomach and aids in gastric motility. It is released by G cells in the stomach, duodenum, 
and the pancreas. Gastrinoma (gastrin-producing tumor) is the second most common 
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secretory pancreatic NET. It can rise from both cells in the duodenum and in the pancreas, 
with just more than half malignant at presentation. Approximately 25% to 35% of 
gastrinomas are associated with MEN1. Gastrinoma is the most common GEP NET 
associated with MEN1. Gastrinomas secrete gastrin but gastrin can circulate in numerous 
forms. Progastrin, gastrin 34, gastrin 17, and C-terminally extended gastrins may all 
circulate in high concentrations in patients with gastrinoma. In the Zollinger-Ellison 
syndrome, gastrin is produced at excessive levels. Normal values are generally less than 100 
pg/mL (2, 5). 
Gastrinoma is not the only cause of hypergastrinemia, since there are several causes for 
hypergastrinemia that often require numerous and expensive diagnostic investigations. 
Hypergastrinemia is most frequently due to hypochlorhydria and only seldom the 
underlying cause is gastrinoma. The most frequent condition that causes hypochlorhydria is 
the use of antacids or medicines that suppress stomach acid. Also autoimmune gastritis, 
where the immune system attacks the parietal cells leading to hypochlorhydria (low 
stomach acidity) is a possible cause. In this condition, hypochlorhydria results in an elevated 
gastrin level in an attempt to compensate for increased pH in the stomach. Eventually, all 
the parietal cells are lost and achlorhydria results to a loss of negative feedback on gastrin 
secretion. Other causes of hypergastrinemia are G-cell hyperplasia (overactivity of gastrin-
producing cells in the stomach), Helicobacter pylori infection of the stomach, mucolipidosis 
type IV (5, 15) (Table 4). 
HYPERGASTRINEMIA WITHOUT GASTRIC ACID HYPERSECRETION: 
Atrophic gastritis (with or without pernicious anemia) 
Gastric cancer without involvement of the gastric antrum 
Therapy with H-2 blockers or proton pump inhibitors (PPIs) 
HYPERGASTRINEMIA WITH GASTRIC ACID HYPERSECRETION: 
Gastrinoma 
Antral G cell hyperplasia 
Duodenal ulcer 
Gastrojejunostomy or Billroth II 
Pyloric stenosis 
Hypercalcemia 
Massive bowel resection 
Chronic renal impairment 
Table 4. Conditions associated with hypergastrinemia 
3.4 VIP 
Vasoactive intestinal peptide (VIP) is a peptide hormone containing 28-amino acid residues. 
It is produced in many areas of the human body including the gut, pancreas and 
suprachiasmatic nuclei of the hypothalamus in the brain.  
In normal physiology VIP acts as a neuromodulator and not as an hormone, since it 
circulates in low quantity even an increase of about 20-50% of normal reference range  is 
significant. VIP is released from neurons, peripheral ganglia, throughout  the GI tract, in the 
urogenital system, respiratory tract and blood vessels. VIP has several effects on the 
digestive system: 
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it relaxes the lower esophageal sphincter ,the fundic smooth muscle and suppress gastric 
acid secretion. These effects work together to increase motility. Like secretin, it stimulates 
secretion of water and bicarbonate and stimulates secretion of chloride and water from large 
intestine; in small intestine inhibits absorption and the contractile effect of CCK. Moreover  
it enhances  the release of insulin and glucagon. VIP has also significant effects on the 
cardiovascular system. It causes coronary vasodilation as well as it has a positive inotropic 
and chronotropic effect. VIP helps to regulate prolactin secretion (2). 
VIPoma is much less common that insulinoma and gastrinoma with an incidence of 
approximately 0.02 per 100,000 per year. VIPoma is characterized by watery diarrhea, 
hypokalemia and achlorhydria (WDHA syndrome or pancreatic cholera syndrome, or also 
called Verner Morrison syndrome). Due to VIP effects as a potent stimulator of intestinal 
secretion and inhibitor of gastric acid secretion, the massive amounts of secreted VIP cause 
profound and chronic watery diarrhea (fasting stool volume > 750 to 1000 mL/day) and 
resultant dehydration, hypokalemia, achlorhydria (hence WDHA-syndrome), acidosis, 
vasodilation (flushing and hypotension), hypercalcemia and hyperglycemia. The watery 
diarrhea  may be  intermittent at the onset , but it may rapidly escalate and reach a volume 
of 15-20L per day, causing profound alteration in fluids and electrolytes control. 
Hypokalemic acidosis is due to bicarbonate and potassium loss across the bowel mucosa; it 
may provoke  asthenia and tetanic contraction. Gastric achlorhydria occurs only in 50% of 
patients, while hypochlorhydria is usually present. Abdominal pain and weight loss are also 
common features. Other signs are hypercalcemia, related to VIP direct action on bone 
metabolism, and flushes that may cause some confusion with classical midgut carcinoid 
syndrome (5) (see above, Table 3). 
The majority of VIPomas occurs in the pancreas, while about 10-15% arises in the  ganglionic 
chain and most common in the adrenal medulla. In children, besides, VIP-producing tumors 
may occur in ganglioneuroma and neuroblastoma. About 50-60% of VIP-secreting tumors 
are malignant and present hepatic involvement. It may arise in contest of MEN1 syndrome 
(2).  
3.5 Glucagon 
Glucagon is a hormone secreted by alpha cells (ǂ-cells) of the islets of Langerhans of the 
pancreas and from the L cells in the intestinal mucosa. Glucagon is a 29-amino acid 
polypeptide and its main action is to raise blood glucose levels. From these two sites, 
proglucagon is processed differently. In the pancreas, proglucagon is processed to produce 
glucagon, glycentin-related peptide, intervening peptide, and the major glucagon fragment. 
Intestinal proglucagon undergoes alternative posttranslational processing that generates 
glycentin, sometimes referred to as gut glucagon, glucagon-like peptide 1 (GLP1), and 
glucagon-like peptide 2 (GLP2) (2). 
Plasma glucagon is a specific marker for Glucagonoma. Glucagonoma occurs at 
approximately the same frequency as VIPoma. Circulating glucagon concentrations are 
typically more than 5-fold higher than the reference range. Both pancreatic glucagon and 
glycentin are measured in high concentrations. Considering the importance of glucagon in 
the control of blood glucose, one would expect a glucagon-secreting tumor to produce a 
profound syndrome. However this is not the case and glucagonoma usually presents late 
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with extensive metastatic spread, mild diabetes, and a characteristic rash (necrolytic 
migratory erythema) (5).  
Increased secretion of glucagon is also caused by other causes, like decreased plasma 
glucose (indirectly), increased catecholamines - norepinephrine and epinephrine, increased 
plasma amino acids (to protect from hypoglycemia if an all-protein meal is consumed), 
sympathetic nervous system, acetylcholine, cholecystokinin. Decreased secretion of 
glucagon is caused by somatostatin, insulin, increased free fatty acids and keto acids into the 
blood, increased urea production (16).  
3.6 Somatostatin 
Somatostatin is a peptide hormone that regulates the endocrine system and affects 
neurotransmission and cell proliferation. Somatostatin is classified as an inhibitory 
hormone, that exerts its effects mainly on anterior pituitary, by inhibiting the release of GH, 
opposing the effects of Growth Hormone-Releasing Hormone (GHRH), and inhibiting the 
release of thyroid-stimulating hormone (TSH) and on gastrointestinal system, by 
suppressing the release of other gastrointestinal and pancreatic hormones, decreasing 
gastric emptying, and reducing smooth muscle contractions and blood flow within the 
intestine (2). 
Pancreatic somatostatinoma is a tumor of the delta cells of the endocrine pancreas that 
produces somatostatin. It is uncommon and symptoms are vague, thus diagnosis is 
frequently delayed. Clinical syndrome is characterized by a triad of : mild diabetes mellitus, 
steatorrhea and gallstones. Also hypochlorhydria can be associated. Patients may present 
with clinical endocrine syndrome due to elevated somatostatin that can cause diabetes 
mellitus, by inhibiting insulin secretion, steatorrhea by inhibiting cholecystokinin and 
secretin, gallstones by inhibiting cholecystokinin which normally induce gallbladder 
myocytes contraction, and hypochlorhydria caused by inhibiting gastrin, which normally 
stimulates acid secretion. However, more frequently patients present with symptoms 
related with tumor bulk. In presence of a somatostatinoma circulating somatostatin 
concentrations may be more than 100 times the reference range (2, 5). 
3.7 Other circulating markers 
3.7.1 Corticotropin-releasing hormone (CRH) 
Corticotropin-releasing hormone, a 41-amino acid peptide derived from a 191-amino acid 
preprohormone, acts as hormone and neurotransmitter  in the stimulation of pituitary  
synthesis of ACTH in stress  response. In normal physiology CRH is produced by 
parvocellular neuroendocrine cells (contained within the paraventricular nucleus of 
hypothalamus). 
Ectopic CRH production is rare, it may occur  in patients with medullary thyroid carcinoma 
(about 33%) and pheochromocytoma (19%), carcinoid (5%) and small cell lung carcinoma 
(about 10 %) and prostate cancer (17). The main clinical feature is Cushing 's syndrome; 
levels of cortisol are elevated (>900 nmol/l) as ACTH, DHEA-S. Overnight administration of 
dexamethasone doesn't suppress cortisol secretion.  
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3.7.2 Growth-hormone-releasing-hormone (GHRH) 
Growth-hormone-releasing-hormone (GHRH) is a 44-amino acid hormone released from 
neurosecretory nerve terminals of the arcuate neurons, and is carried by the hypothalamic- 
hypophyseal portal system to anterior pituitary gland, where stimulates growth hormone 
(GH) secretion. Hypothalamic tumors, including hamartomas, choristomas, gliomas, and 
gangliocytomas, may produce excessive GHRH with subsequent GH hypersecretion and 
resultant acromegaly. Peripheral GHRH levels are not elevated in patients with 
hypothalamic GHRH-secreting tumors, supporting the notion that excess eutopic 
hypothalamic GHRH secretion into the hypophyseal portal system does not appreciably 
enter the systemic circulation. Excessive ectopic  peripheral production of GHRH is present 
in several tumors, including carcinoid tumors, pancreatic cell tumors, small-cell lung 
cancers, adrenal adenomas, and pheochromocytomas, which have been reported to secrete 
GHRH. In these cases, peripheral GHRH levels are elevated even if acromegaly in these 
patients, is uncommon. For these reasons measuring GHRH plasma levels provides a 
precise and cost-effective test for the diagnosis of ectopic acromegaly. Elevated circulating 
GHRH levels, a normal or small-size pituitary gland, or clinical and biochemical features of 
other tumors known to be associated with extra-pituitary acromegaly, are all indications for 
extra-pituitary production of GHRH (18). 
3.7.3 Calcitonin  
Calcitonin is a 32-amino acid peptide released, in normal physiology, only in  non-follicular 
C-cells of the thyroid . It is produced as a 136-amino acid precursor (pro-calcitonin) and 
processed in  secretory granules to the active form. The synthesis and release of calcitonin 
are closely related to calcium serum levels. Calcitonin is raised in medullary thyroid cancer, 
where concentration may be thousands-fold the reference range. Medullary thyroid cancers 
frequently arise as part of multiple endocrine neoplasia type 2 (MEN2)  syndrome. 
Calcitonin may also be raised in some pancreatic neuroendocrine tumor, especially those 
that are multi-hormone producing and bronchial carcinoid. Usually ectopic-produced  
calcitonin is a large molecule without biochemical activity (2). 
4. Provocative tests 
4.1 Insulinoma: 72-hour fast 
NETs secreting insulin are termed insulinomas and are almost exclusively intrapancreatic in 
nature. Insulinomas secrete proinsulin, insulin and C-peptide intermittently, and, although 
insulin concentrations in the circulation may often be within reference range, insulin is at 
most times inappropriately high for the blood glucose concentration. 
The diagnosis is suggested in the presence of the Whipple’s triad: symptoms of 
hypoglycemia, glucose < 2.5 mmol/l (45 mg/dl) and relief of symptoms with administration 
of glucose. Hypoglycemia-induced clinical signs are classically present in the early morning 
pre-prandial phase or maybe exercise-induced. The typical signs are due to activation of 
adrenergic nervous system (palpations, sweating pallor, anxiety) and neuroglycopenia 
(personality changes, and loss of consciousness). The latter symptom reflects both the 
severity and duration of hypoglycemia. Although these symptoms are profound, they may 
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be intermittent and diagnosis is not always straightforward. The 72-hour fast is the gold 
standard for diagnosing insulinoma and it attests  autonomous insulin secretion and the 
failure of appropriate insulin suppression in the presence of hypoglycemia. In fact, a 
carefully supervised 72-hour starvation usually precipitates hypoglycemia within the first 
36 to 48 hours. A 72-hour period is universally recognized as the most appropriate duration 
although some groups have proposed a shorter fast of 48 h. Symptoms appear within 12 h 
for one third of patients, 80% within 24 h, 90% with 48 h and approaching 100% within 72 h. 
Absolute values of glucose and insulin are the most important variables and any measurable 
insulin is abnormal when blood glucose drops to 2.5 mol/l (45 mg/dl). The patient should 
be monitored in a supervised environment and fasting should be accompanied by an 
intravenous line. Absolute blood (venous) determinations should be performed at least 2–4 
times per day and bedside measurements can be used in the presence of  clinical symptoms 
to determine if more definitive measurements should be made. Blood should also be drawn 
for insulin measurement concurrently with glucose estimations, and assay for insulin and C-
peptide when the hypoglycemia is confirmed. The differential diagnosis is insulin abuse 
(known insulin-requiring diabetes or factitious hypoglycemia): it can be detected when 
insulin is increased but not pro-insulin or C-peptide, so the measurement of increased pro-
insulin or C-peptide secures the diagnosis of insulinoma. On rare  occasions the abuse of 
sulphonylureas and related insulin secretagogues result in a clinical picture similar to 
patients with insulinoma and may be diagnosed only by a positive drug screen. Even  
patients on regular therapy with oral hypoglycemic medications in the setting of renal 
impairment may show symptoms that mimic insulinoma (5, 7). 
4.2 Gastrinoma: Secretin test 
Gastrinoma is the second most common secretory pancreatic NET with just more than half 
malignant at presentation. Gastrinoma is the most common GEP NET associated with 
MEN1, with approximately 25-35%of gastrinomas being associated with MEN1. 
Gastrinomas may be found in the duodenum (50-70%) and less commonly in the pancreas 
(20-40%) and secrete excess of gastrin, leading to ulceration in the stomach, duodenum 
and the small intestine. Hydrochloric acid (HCl) also causes hyperperistalsis and inhibits 
the activity of lipase causing severe diarrhea. The clinical syndrome is therefore 
characterized by the classical triad of gastric acid hypersecretion, severe peptic ulceration, 
and non-beta cell islet tumor of pancreas (gastrinoma) and this is called Zollinger Ellison 
syndrome (ZES). Despite a clear clinical syndrome, the primary gastrinoma may be often  
smaller than can be visualized by any current radiological method. Therefore, circulating 
gastrin remains a useful tool for diagnosis. The diagnosis of ZES can be established by the 
demonstration of elevated fasting serum gastrin (FSG) in the presence of low gastric pH 
(<5.0). In fact, in the presence of gastric acid (pH<5.0), a serum gastrin value greater than 
1000 pg/mL is virtually diagnostic of the disorder. However, about two-thirds of patients 
with the Zollinger-Ellison syndrome have serum gastrin concentrations less than 10 times 
the upper limit of normal (generally between 150 and 1000 pg/mL), so FSG alone is not 
adequate for a conclusive diagnosis of ZES. Moreover hypergastrinemia can be seen in 
patients with achlorhydria associated with chronic atrophic fundus gastritis (e.g., 
pernicious anemia), proton pump inhibitor drugs and in other conditions with 
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hyperchlorhydria (e.g., Helicobacter pylori infection, gastric outlet obstruction, renal 
failure, antral G cell syndromes, short bowel syndrome, retained antrum) (see above 
Table 4) (2).  
The secretin stimulation test can differentiate patients with gastrinomas from those with 
hypergastrinemia of different etiologies and identify those patients with gastrinoma and 
only mild hypergastrinemia (Figure 2). Secretin is normally secreted by duodenal S-cells in 
response to a low luminal pH following food-stimulated acid secretion. Its primary action is 
to cause the release of bicarbonate rich pancreatic juice from pancreatic acinar cells, thus 
neutralizing the acidic juice delivered from the stomach. Under physiological conditions, 
secretin decreases antral gastrin secretion. However in presence of a gastrinoma, secretin 
stimulates the release of stored gastrin by gastrinoma cells, and therefore most patients with 
these tumors have a dramatic rise in serum gastrin in response to a secretin infusion. In 
contrast, normal gastric G cells are inhibited by secretin, and therefore serum gastrin 
concentrations do not rise in patients with other causes of hypergastrinemia. The 
secretin stimulation test is performed by administering 2 U of secretin/kg body weight 
intravenously over one minute; a baseline serum gastrin is measured twice before the 
secretin is administered and 2, 5, 10, 15, and 20 minutes later. Several criteria have been 
proposed to define a positive test; the most commonly accepted one is a rise in serum 
gastrin by 200 pg/mL (95 pmol/L) or more, which is diagnostic for the presence of 
gastrinoma in more than 90% of cases. The use of this test has recently been re-evaluated, 
suggesting a lower cut-off (a rise >120 pg/mL in serum gastrin concentration) to define a 
positive test, thus obtaining an increase in the sensitivity (94%) without loss of specificity 
(100%) (7, 15). 
 
Fig. 2. Suggested algorithm for the investigation of hypergastrinemia. 
Elevated fasting serum gastrin
Gastric juice pH
pH < 5
Gastrin >1000 pg/mL 
pH > 5
Gastrin < 1000 pg/mL  
Provocation test 
(secretin) 
ZES
Tumor localization  
and staging 
Stop Antacid drugs 
MEN1  
Upper endoscopy with 
multiple biopsies 
Atrophic gastritis 
Autoimmune? 
(APCA) 
Helicobacter 
Pylori ? 
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Another critical point regarding secretin test is to establish whether the the same diagnostic 
operative characteristics of the test remains unchanged even during treatment with inhibitors 
of acid secretion. In fact the standard secretin test was performed with patients off antacids 
and anticholinergics for at least 12 hours and H2 antagonists and proton pump inhibitors were 
not available at the  time the test was described. However, patients with severe ZES can 
develop complications (such as acute bleeding and perforation) if acid suppression is 
discontinued. Thus, discontinuation of acid suppression should be performed cautiously. 
While the accuracy of the test in patients taking proton pump inhibitors (PPIs) has not been 
well established, some authors suggest that PPIs do not interfere with the interpretation of the 
secretin stimulation test and that PPIs do not need to be discontinued. However, the leading 
experts suggest PPIs should be discontinued for one-two weeks (1, 7, 10). 
The secretin stimulation test has also been shown to be a valuable predictor of recurrence of 
gastrinoma following surgery (15). 
4.3 Other provocative tests for gastrinoma 
In addition to the secretin test, several other stimulation tests have been developed to 
attempt to differentiate between neoplastic and non-neoplastic causes of hypergastrinemia. 
These include calcium, meal and glucagon stimulation tests. 
4.3.1 Calcium stimulation test 
The calcium provocation test is based on the principle that calcium administration 
stimulates the release of stored gastrin from gastrinoma cells, as well as for secretin test. 
Serum gastrin concentrations are measured at 0, 30, 60, 90, 120, 150, 180 minutes intervals 
during an intravenous infusion of 10% calcium gluconate (5 mg/kg body weight over 3 h). 
More than 80% of gastrinoma patients show an increase in serum gastrin of >200 pg/mL 
within the third hour of calcium infusion, usually with a positive response at 120 to 180 min. 
The sensitivity of this test is low (about 43%), thus it can’t replace the secretin test, but it 
could be used in patients with an high clinical suspicion of ZES and a negative secretin test 
(15). 
4.3.2 Meal stimulation test 
The physiological response to a standard test meal (of two eggs and toast) is an increase in 
plasma gastrin of up to two to threefold. Patients with ZES demonstrate no or only a very 
minimal increase in serum gastrin concentration after ingestion of such a protein rich test 
meal, whereas patients with other causes of hypergastrinemia show a more pronounced 
increase in serum gastrin following the same protein test meal. However, data on these 
results seems to be conflicting and a significant overlap in patients with ZES and with other 
antral syndromes is observed, thus the meal stimulation test for investigation of the cause of 
hypergastrinemia is not currently recommended (15). 
4.3.3 Glucagon stimulation test 
Glucagon stimulation test consists in a rise in serum gastrin concentration following the 
administration of glucagon to patients with ZES, but a paradoxical fall in serum gastrin 
www.intechopen.com
 
Circulating Markers in Gastroenteropancreatic Endocrine Tumors (GEP NETs) 
 
35 
concentrations in patients with pernicious anemia. This test has not been widely evaluated; 
however, further studies are required to determine the overall accuracy of the glucagon 
stimulation test (15). 
5. Conclusions 
Numerous biochemical markers have been identified in association with GEP-NETs, but few 
have the specificity or predictive value of CgA or urinary 5-HIAA, and their measurement is 
complex. Recent studies have proposed that alkaline phosphatase and neurokinin A are 
better predictors of survival in metastatic NETs than CgA but additional rigorous data to 
support this assertion are required.  
Circulating biomarkers offer a useful diagnostic tool in conjunction with radiology and 
tissue pathology for NETs. However, these biomarkers are more reliable when used to 
monitor disease progression, response to treatment, and for early detection of recurrence 
after treatment. 
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